Literature DB >> 23132868

Disease-associated mutations in the prion protein impair laminin-induced process outgrowth and survival.

Cleiton F Machado1, Flavio H Beraldo, Tiago G Santos, Dominique Bourgeon, Michele C Landemberger, Martin Roffé, Vilma R Martins.   

Abstract

Prions, the agents of transmissible spongiform encephalopathies, require the expression of prion protein (PrP(C)) to propagate disease. PrP(C) is converted into an abnormal insoluble form, PrP(Sc), that gains neurotoxic activity. Conversely, clinical manifestations of prion disease may occur either before or in the absence of PrP(Sc) deposits, but the loss of normal PrP(C) function contribution for the etiology of these diseases is still debatable. Prion disease-associated mutations in PrP(C) represent one of the best models to understand the impact of PrP(C) loss-of-function. PrP(C) associates with various molecules and, in particular, the interaction of PrP(C) with laminin (Ln) modulates neuronal plasticity and memory formation. To assess the functional alterations associated with PrP(C) mutations, wild-type and mutated PrP(C) proteins were expressed in a neural cell line derived from a PrP(C)-null mouse. Treatment with the laminin γ1 chain peptide (Ln γ1), which mimics the Ln binding site for PrP(C), increased intracellular calcium in cells expressing wild-type PrP(C), whereas a significantly lower response was observed in cells expressing mutated PrP(C) molecules. The Ln γ1 did not promote process outgrowth or protect against staurosporine-induced cell death in cells expressing mutated PrP(C) molecules in contrast to cells expressing wild-type PrP(C). The co-expression of wild-type PrP(C) with mutated PrP(C) molecules was able to rescue the Ln protective effects, indicating the lack of negative dominance of PrP(C) mutated molecules. These results indicate that PrP(C) mutations impair process outgrowth and survival mediated by Ln γ1 peptide in neural cells, which may contribute to the pathogenesis of genetic prion diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23132868      PMCID: PMC3527962          DOI: 10.1074/jbc.M112.428235

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  77 in total

1.  The mechanism of internalization of glycosylphosphatidylinositol-anchored prion protein.

Authors:  Claire Sunyach; Angela Jen; Juelin Deng; Kathleen T Fitzgerald; Yveline Frobert; Jacques Grassi; Mary W McCaffrey; Roger Morris
Journal:  EMBO J       Date:  2003-07-15       Impact factor: 11.598

Review 2.  Cell cycle regulation and neural differentiation.

Authors:  Umberto Galderisi; Francesco Paolo Jori; Antonio Giordano
Journal:  Oncogene       Date:  2003-08-11       Impact factor: 9.867

Review 3.  Allosteric function and dysfunction of the prion protein.

Authors:  Rafael Linden; Yraima Cordeiro; Luis Mauricio T R Lima
Journal:  Cell Mol Life Sci       Date:  2011-10-09       Impact factor: 9.261

4.  The cellular prion protein mediates neurotoxic signalling of β-sheet-rich conformers independent of prion replication.

Authors:  Ulrike K Resenberger; Anja Harmeier; Andreas C Woerner; Jessica L Goodman; Veronika Müller; Rajaraman Krishnan; R Martin Vabulas; Hans A Kretzschmar; Susan Lindquist; F Ulrich Hartl; Gerd Multhaup; Konstanze F Winklhofer; Jörg Tatzelt
Journal:  EMBO J       Date:  2011-03-25       Impact factor: 11.598

5.  Common structural traits across pathogenic mutants of the human prion protein and their implications for familial prion diseases.

Authors:  Giulia Rossetti; Xiaojing Cong; Rocco Caliandro; Giuseppe Legname; Paolo Carloni
Journal:  J Mol Biol       Date:  2011-06-12       Impact factor: 5.469

6.  Quantification of surviving cerebellar granule neurones and abnormal prion protein (PrPSc) deposition in sporadic Creutzfeldt-Jakob disease supports a pathogenic role for small PrPSc deposits common to the various molecular subtypes.

Authors:  B A Faucheux; E Morain; V Diouron; J-P Brandel; D Salomon; V Sazdovitch; N Privat; J-L Laplanche; J-J Hauw; S Haïk
Journal:  Neuropathol Appl Neurobiol       Date:  2011-08       Impact factor: 8.090

7.  Cytosolic prion protein is not toxic and protects against Bax-mediated cell death in human primary neurons.

Authors:  Xavier Roucou; Qi Guo; Yan Zhang; Cynthia G Goodyer; Andrea C LeBlanc
Journal:  J Biol Chem       Date:  2003-08-12       Impact factor: 5.157

8.  Prion protein prevents human breast carcinoma cell line from tumor necrosis factor alpha-induced cell death.

Authors:  Maryam Diarra-Mehrpour; Samuel Arrabal; Abdelali Jalil; Xavier Pinson; Catherine Gaudin; Geneviève Piétu; Amandine Pitaval; Hugues Ripoche; Marc Eloit; Dominique Dormont; Salem Chouaib
Journal:  Cancer Res       Date:  2004-01-15       Impact factor: 12.701

9.  Small protease sensitive oligomers of PrPSc in distinct human prions determine conversion rate of PrP(C).

Authors:  Chae Kim; Tracy Haldiman; Krystyna Surewicz; Yvonne Cohen; Wei Chen; Janis Blevins; Man-Sun Sy; Mark Cohen; Qingzhong Kong; Glenn C Telling; Witold K Surewicz; Jiri G Safar
Journal:  PLoS Pathog       Date:  2012-08-02       Impact factor: 6.823

10.  Depleting neuronal PrP in prion infection prevents disease and reverses spongiosis.

Authors:  Giovanna Mallucci; Andrew Dickinson; Jacqueline Linehan; Peter-Christian Klöhn; Sebastian Brandner; John Collinge
Journal:  Science       Date:  2003-10-31       Impact factor: 47.728

View more
  3 in total

1.  Prion protein as a mediator of synaptic transmission.

Authors:  Joern R Steinert
Journal:  Commun Integr Biol       Date:  2015-08-14

2.  Prion protein facilitates synaptic vesicle release by enhancing release probability.

Authors:  Susan W Robinson; Marie L Nugent; David Dinsdale; Joern R Steinert
Journal:  Hum Mol Genet       Date:  2014-04-09       Impact factor: 6.150

3.  Hampering the early aggregation of PrP-E200K protein by charge-based inhibitors: a computational study.

Authors:  Mariangela Agamennone; Loriano Storchi; Alessandro Marrone; Roberto Paciotti
Journal:  J Comput Aided Mol Des       Date:  2021-06-10       Impact factor: 3.686

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.